{"id":"W2313308264","doi":"10.1097/mib.0000000000000720","title":"O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohnʼs Disease Refractory to Anti-TFNα","year":2016,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Robarts Clinical Trials","funders":"","keywords":"Medicine; Ustekinumab; Placebo; Refractory (planetary science); Internal medicine; Clinical endpoint; Gastroenterology; Crohn's disease; Adverse effect; Randomization; Dosing; Randomized controlled trial; Antagonist; Intention-to-treat analysis; Disease; Infliximab; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001229998,0.001714042,0.002213795,0.0003951655,0.0005517025,0.0008685833,0.0007391329,0.001677618,0.007940488],"category_scores_gemma":[0.0008874692,0.0006849354,0.0009884227,0.0002820061,0.001138699,0.0008031153,0.000343494,0.003419472,0.001690173],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004176122,"about_ca_system_score_gemma":0.001615001,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007422748,"about_ca_topic_score_gemma":0.001713754,"domain_scores_codex":[0.9996446,0.0001430661,0.00001771804,0.00006965498,0.00003159399,0.00009324351],"domain_scores_gemma":[0.999299,0.0001344186,0.00009553307,0.000047636,0.00005229052,0.0003710693],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9179211,0.03391959,0.0008692536,0.00051328,0.0003244374,0.00008523875,0.00009521592,0.0003304753,0.01915184,0.000246215,0.00248732,0.02405603],"study_design_scores_gemma":[0.7342793,0.2601364,0.002028138,0.00002121297,0.0001264887,0.00004968538,0.00001862179,0.000362815,0.001411012,0.0001517721,0.001398719,0.00001584665],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9784349,0.001856774,0.001060444,0.0006696691,0.000350529,0.008891001,0.00203908,0.0002903303,0.006407223],"genre_scores_gemma":[0.9743649,0.00147255,0.002913201,0.001911251,0.0004270806,0.006596725,0.002943703,0.00007256286,0.009297942],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007940488,"threshold_uncertainty_score":0.02656364,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01905318042425172,"score_gpt":0.2829108564889205,"score_spread":0.2638576760646688,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}